Rapalink-1 Targets Glioblastoma Stem Cells and Acts Synergistically with Tumor Treating Fields to Reduce Resistance against Temozolomide. (2020)

First Author: Vargas-Toscano A
Attributed to:  Wellcome Trust MRC Cambridge Stem Cell Institute funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3390/cancers12123859

PubMed Identifier: 33371210

Publication URI: http://europepmc.org/abstract/MED/33371210

Type: Journal Article/Review

Volume: 12

Parent Publication: Cancers

Issue: 12

ISSN: 2072-6694